On June 24, 2022, Hexima Limited announced that based on its preliminary review, the results of its phase II clinical study of pezadeftide for the treatment of onychomycosis (HXP124-ONY-002) are inconclusive and will require further detailed investigation and evaluation. The results seen in this study do not appear to correlate with results observed in its prior phase I study (HXP124-ONY-001) and do not support moving directly into a phase III program. Hexima intends to conduct a detailed review of the complete clinical trial data set and study conduct and expects to report its findings when complete.
Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
0.011 AUD | 0.00% | -15.38% | -38.89% |
22/03 | Hexima Secures R&D Tax Rebate for Fiscal Year 2023 | MT |
19/03 | Hexima Changes Address | MT |
Annual profits - Rate of surprise
1st Jan change | Capi. | |
---|---|---|
-38.89% | 1.22M | |
+25.69% | 47.9B | |
+46.90% | 41.42B | |
-3.46% | 40.7B | |
-6.20% | 28.92B | |
+9.17% | 25.55B | |
-20.42% | 19.27B | |
+0.17% | 12.15B | |
+28.07% | 12.14B | |
-1.24% | 11.99B |
- Stock Market
- Equities
- HXL Stock
- News Hexima Limited
- Hexima Limited Announces Preliminary Results of Phase II Clinical Study of Pezadeftide